Results 101 to 110 of about 138,032 (344)

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement–interleukin-1β loop

Haematologica, 2019
Enhanced peripheral complement activation has long been considered as one of the major pathogenic elements of immune thrombocytopenia. A dysfunctional bone marrow microenvironment, especially with regards to mesenchymal stem cells, has been observed in ...
Xiaolu Zhu, Yanan Wang, Qian Jiang, Hao Jiang, Jin Lu, Yazhe Wang, Yuan Kong, Yingjun Chang, Lanping Xu, Jun Peng, Ming Hou, Xiaojun Huang, Xiaohui Zhang   +12 more
doaj   +1 more source

CYTOKINE STORM 15 DAYS AFTER VIRAL-INDUCED VACCINE, MACROPHAGIC ACTIVATION SYNDROME OR VACCINE-INDUCED IMMUNE THROMBOCYTOPENIA (VITT) SYNDROME?

, 2022
Hicham Ziani, A. Azzouzi, A. Elhijri, R. Elmoussaoui   +3 more
openalex   +1 more source

Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia [PDF]

, 2020
Min Ji Jeon, Eun Sang Yu, Ka‐Won Kang, Byung‐Hyun Lee, Yong Park, Se Ryeon Lee, Hwa Jung Sung, Soo Yong Yoon, Chul Won Choi, Byung Soo Kim, Dae Sik Kim   +10 more
openalex   +1 more source

Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting –Adjusted Comparison to a Historical Control Group Treated With Belimumab

Arthritis &Rheumatology, EarlyView.
Objective The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.
Chong Luo, Shu Su, Jingyue Liu, Junyu Lin, Jin Song, Zongwen Chen, Yuanyuan Peng, Lijun Jiang, Meng Jia, Li Wang, Xinhui Jiang, Wei Zhang, Zanhua Rong, Bo Zhao, Yajun Wang, Xuemei Tang   +15 more
wiley   +1 more source

Experimental Models of Thrombocytopenia in Laboratory Animals and their Application in Identifying the Complications of Chemotherapy Drugs

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2018
BACKGROUND AND OBJECTIVE: Thrombocytopenia is one of the complications of chemotherapy drugs that may cause death. Different animal models of thrombocytopenia are used for clinical research and identification of its causes, each with advantages and ...
H Kamali, MR Khazaei, E Shobeiri, M Khazaei   +3 more
doaj  

Metronidazole caused profound drug‐induced immune thrombocytopenia

Clinical Case Reports, 2018
Key Clinical Message Metronidazole is commonly prescribed and has not been known to cause drug‐induced immune thrombocytopenia. We have provided clinical and laboratory evidence with DDabs that metronidazole can cause drug‐induced immune thrombocytopenia
Jeffrey Lew, Jeffrey Berenberg
doaj   +1 more source

Immune Thrombocytopenia as a Consequence of Rocky Mountain Spotted Fever

Case Reports in Oncology, 2017
Primary immune thrombocytopenia (ITP) – also called idiopathic thrombocytopenic purpura or immune thrombocytopenic purpura – is an acquired thrombocytopenia caused by autoantibodies against platelet antigens.
Cherisse Baldeo, Karan Seegobin, Lara Zuberi   +2 more
doaj   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source